NCT00535119View on ClinicalTrials.gov

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

October 31, 2012

Conditions
Adult Solid NeoplasmBRCA1 Mutation CarrierBRCA2 Mutation CarrierHereditary Breast and Ovarian Cancer Syndrome
Interventions
DRUG

Carboplatin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel

Given IV

OTHER

Pharmacological Study

Correlative studies

DRUG

Veliparib

Given PO

Trial Locations (7)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

University of Pittsburgh Cancer Institute, Pittsburgh

30322

Emory University/Winship Cancer Institute, Atlanta

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

95817

University of California Davis Comprehensive Cancer Center, Sacramento

17033-0850

Penn State Milton S Hershey Medical Center, Hershey

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00535119 - Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer | Biotech Hunter | Biotech Hunter